0.005% recombinant human EGF spray twice daily
Context: Phase 3 randomized trial PMID 29902542
Formulation: Concentration, vehicle, treated area, and product sterility are formulation-specific.
Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.